AZN - Latest News
AstraZeneca PLC (AZN), operates in Healthcare / Drug Manufacturers - General, trades on NYSE.
Market capitalization stands near $241.66B. Trailing twelve-month P/E ratio is 23.59. Beta to the broader market is 0.21.
The article list below shows the most recent AZN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent AZN Headlines
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint
defenseworld.net - Oct 13, 2026
Astrazeneca (NYSE: AZN) presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at th
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript
seekingalpha.com - Oct 12, 2026
AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting Transcript
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint
marketbeat.com - Oct 12, 2026
Astrazeneca NYSE: AZN presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the
AstraZeneca's efzimfotase alfa adult data point to $4.4bn peak sales potential, says Citi
proactiveinvestors.com - Oct 12, 2026
Citi has maintained its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) with a target price of £186, arguing that detailed trial data for its ra
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
businesswire.com - Oct 8, 2026
PALO ALTO, Calif. --(BUSINESS WIRE)--Guardant Health, Inc.
How News Affects AZN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track AZN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked AZN news questions
- What is the latest AZN news headline?
- The most recent AZN headline (Oct 13, 2026) is "AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the AZN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What AZN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual AZN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.